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A n g io te n s in -c o n v e r t in g  e n z y m e  (A CE) p r o d u c e s  th e  
v a s o c o n s t r i c to r  a n g io te n s in  II . T h e  A C E  p r o t e in  is  c o m ­
p o s e d  o f  tw o  h o m o lo g o u s  d o m a in s , e a c h  b in d in g  z in c  
a n d  e a c h  in d e p e n d e n t ly  c a ta ly t i c .  T o  a s s e s s  th e  p h y s io ­
lo g ic  s ig n if ic a n c e  o f  th e  tw o  A C E  c a ta ly t i c  d o m a in s , w e  
u s e d  g e n e  t a r g e t i n g  in  m ic e  to  in t r o d u c e  tw o  p o in t  m u ­
ta t io n s  (H 395K  a n d  H 399K ) t h a t  s e le c t iv e ly  in a c t iv a t e d  
th e  A C E  N - te r m in a l  c a ta ly t i c  s i te .  T h is  m o d i f ic a t io n  
d o e s  n o t  a f f e c t  C - te r m in a l  e n z y m a tic  a c t iv i ty  o r  A C E  
p r o t e in  e x p re s s io n .  I n  a d d i t io n ,  th e  te s t i s  A C E  iso z y m e  
is  n o t  a f f e c te d  b y  th e  m u ta t io n s .  A n a ly s is  o f  h o m o z y g o u s  
m u t a n t  m ic e  ( te rm e d  A C E  7/7) s h o w e d  n o r m a l  p la s m a  
le v e ls  o f  a n g io t e n s in  I I  b u t  a n  e le v a t io n  o f  p la s m a  a n d  
u r i n e  iV -ace ty l-S e r-A sp -L y s-P ro , a  p e p t id e  s u g g e s te d  to  
i n h i b i t  b o n e  m a r r o w  m a t u r a t io n .  D e s p ite  th i s ,  A C E  7/7 
m ic e  h a d  b lo o d  p r e s s u r e ,  r e n a l  f u n c t io n ,  a n d  h e m a to c r i t  
t h a t  w e re  in d i s t in g u i s h a b le  f ro m  w ild - ty p e  m ic e . W e 
a ls o  s tu d ie d  c o m p o u n d  h e te r o z y g o u s  m ic e  in  w h ic h  o n e  
A C E  a l le le  w a s  n u l l  (n o  A C E  e x p re s s io n )  a n d  th e  s e c o n d  
a l le le  e n c o d e d  th e  m u ta t i o n s  s e le c t iv e ly  in a c t iv a t in g  th e  
N - te r m in a l  c a ta ly t i c  d o m a in . T h e s e  m ic e  p r o d u c e d  a p ­
p ro x im a te ly  h a l f  th e  n o r m a l  le v e ls  o f  A C E , w i th  th e  A C E  
p r o t e in  la c k in g  N - te r m in a l  c a ta ly t i c  a c t iv i ty .  D e s p ite  
th i s ,  th e  m ic e  h a v e  a  p h e n o ty p e  in d i s t in g u i s h a b le  f ro m  
w ild - ty p e  a n im a ls .  T h is  s tu d y  s h o w s  th a t ,  in  v iv o , th e  
p r e s e n c e  o f  th e  C - te r m in a l  A C E  c a ta ly t i c  d o m a in  is  s u f ­
f i c ie n t  to  m a in ta in  a  f u n c t io n a l  r e n in - a n g io te n s in  s y s ­
te m . I t  a ls o  s t r o n g ly  s u g g e s ts  t h a t  th e  a n e m ia  p r e s e n t  in  
A C E  n u l l  m ic e  is  n o t  d u e  to  th e  a c c u m u la t io n  o f  th e  
p e p t id e  iV -ace ty l-S e r-A sp -L y s-P ro .
The major role of the renin-angiotensin system ( RAS )1 is the 
regulation of electrolyte homeostasis and blood pressure in 
mammals. The major effector peptide of the RAS is the octapep- 
tide angiotensin II, which raises blood pressure through a
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variety of mechanisms, including vasoconstriction and the con­
trol of aldosterone release. Angiotensin II is the product of two 
successive enzymatic cleavages of angiotensinogen. First, renin 
releases the intermediate decapeptide angiotensin I. Then the 
last two C terminus amino acids of angiotensin I are removed 
by the zinc-metallopeptidase, angiotensin-converting enzyme 
(ACE) (1). ACE inhibitors markedly reduce the formation of 
angiotensin II and are widely used in the treatm ent of hyper­
tension, congestive heart failure, and diabetic nephropathy.
In mammals, two isozymes of ACE have been described (2). 
One isozyme, termed somatic ACE, is made by a variety of 
somatic tissues, including vascular endothelium, proximal tu ­
bular epithelium of the kidney, macrophages, and intestinal 
epithelium. The other isozyme is only produced by germ cells in 
the testis and is called testis ACE (3, 4). The study of ACE 
knock-out mice has provided convincing evidence that testis 
ACE is critical in male fertility. The two ACE isozymes are 
produced by the same gene from two different promoters (3).
In mouse, somatic ACE is a single polypeptide chain com­
posed of 1,312 amino acids (5). Somatic ACE is an ectoenzyme 
where the majority of the protein is exported from cells by an 
N-terminal signal sequence. However, ACE remains bound to 
cell membranes by a C terminus hydrophobic domain and a 
short intracellular domain. Structural analysis of somatic ACE 
has shown that the extracellular region of the protein is com­
posed of two homologous domains, each containing the HEXXH 
consensus active site motif typical of zinc-metallopeptidases. 
Each of these two domains, often termed the N- and C-terminal 
domains, is independently catalytic (6).
Although renin is an extremely specific enzyme that only 
cleaves angiotensinogen, ACE is active on a large number of 
natural substrates, including angiotensin I, bradykinin, Sub­
stance P, luteinizing hormone-releasing hormone, and the he- 
moregulatory peptide iV-acetyl-Ser-Asp-Lys-Pro ( AcSDKP). In  
vitro studies demonstrated tha t both the N- and C- domains 
can hydrolyze angiotensin I, bradykinin, and substance P (6­
8). However, some significant biochemical differences exist be­
tween the two functional domains of ACE ( 9 ). First, while both 
the N- and C- domains are activated by chloride ions, the 
C-terminal site is highly dependent on their concentration and 
is inactive in their absence. In contrast, the N-terminal cata­
lytic domain is maximally activated with lower concentrations 
of chloride ions and retains residual catalytic activity even in 
their absence. Second, the two catalytic sites show differences 
in binding and interaction with competitive inhibitors. For 
example, lisinopril is a more effective inhibitor of the C-termi­
nal catalytic site, whereas captopril has a higher affinity for the 
N-terminal site. Third, and perhaps most important, the two 
catalytic sites differ in their affinity and effectiveness in cleav­



















ing individual peptide substrates. For instance, whereas angio­
tensin I is cleaved with similar kinetics by the two catalytic 
domains, luteinizing hormone-releasing hormone is preferen­
tially cleaved by the N terminus. AcSDKP, thought to be an 
inhibitor of bone marrow proliferation, is catalyzed almost ex­
clusively by the N-terminal catalytic domain of ACE (10). Al­
though the specificity of the two ACE catalytic domains has 
been studied extensively in vitro, virtually nothing is known 
about their relative roles in vivo. Thus, the physiologic rele­
vance of each of the two catalytic domains is unknown.
Knock-out mice lacking all ACE activity present with a com­
plex phenotype (11, 12). These animals have a reduction of 
systolic blood pressure greater than 35 mm Hg as compared 
with wild-type animals. ACE knock-out mice have reduced 
aldosterone production and elevated serum concentrations of 
potassium. The mice are unable to effectively concentrate urine 
and, even in the absence of water restriction, produce larger 
amounts of a more dilute urine than wild-type mice. These 
functional renal defects accompany structural kidney malfor­
mations typified by underdevelopment of the renal medulla 
and papilla. Finally, ACE knock-out mice have a significant 
and highly reproducible anemia. There are two controversial 
hypotheses about the mechanism of impaired hematopoiesis in 
ACE-deficient mice. The first mechanism involves the accumu­
lation of the hemoregulator tetrapeptide AcSDKP in the 
plasma of these mice. AcSDKP has been described as an inhib­
itor of bone marrow proliferation, acting to prevent the recruit­
ment of stem cells into S phase (13). The second hypothesis 
explains the anemia as only due to the lack of angiotensin II 
and is supported by the correction of the hematocrit in ACE 
knock-out mice treated with angiotensin II (14).
To assess the physiologic significance of each of the two ACE 
catalytic domains, we used gene targeting to create a mouse 
model where the ACE gene was mutated to specifically inacti­
vate its N-terminal catalytic site. This modification does not 
affect the C-terminal site or the expression level of ACE pro­
tein. In addition, expression of testis ACE is normal in this 
model. Analysis of these mice showed that their blood pressure, 
renal function, and hematocrit were indistinguishable from 
wild-type mice. We also studied compound heterozygous mice 
in which one ACE allele was null (no ACE expression ), and the 
second allele contained the mutations selectively inactivating 
the N-terminal catalytic domain. These animals produced 
roughly half the normal levels of the ACE protein and the ACE 
protein made lacks N-terminal catalytic activity. These mice 
also have a phenotype indistinguishable from wild-type mice. 
Thus, this study demonstrates that the presence of the C- 
terminal ACE catalytic domain is sufficient to maintain a func­
tional RAS. It also strongly suggests tha t the anemia present in 
ACE null mice is not because of the accumulation of the peptide 
AcSDKP.
M A T E R IA L S  A N D  M E T H O D S
Creation o f  H om ozygous M u ta n t Mice—A 10.7-kb fragm ent of mouse 
genomic DNA was cloned from a mouse ES cell library derived from 
mouse stra in  129. This contained 2.4 kb of the  somatic ACE promoter 
and 8.3 kb encompassing somatic ACE exons 1-12. A 3.8-kb EcoRI 
fragm ent containing exons 7-12 was subcloned, and site-directed mu­
tagenesis was used to create the  point m utations H395K and H399K in 
exon 8 of somatic ACE. These specific amino acid changes were previ­
ously reported to inactivate the enzymatic activity of the  ACE N- 
term inal catalytic site (6). A second round of mutagenesis was then 
performed to create a Bell restriction site within intron 7 of somatic 
ACE. After reconstitution of the 10.7-kb segm ent of genomic DNA. a 
self-excising neomycin cassette (CAN-1, GenBank™/AF169416) (15) 
was cloned into the  intron 7 Bell site. Finally, a thymidine kinase 
cassette was added a t the 5'-end of the 10.7-kb segment. The targeting 
construct was linearized and electroporated into Rl ES cells (16). After 
positive and negative selection, individual ES cell clones were isolated
and screened for targeted homologous recombination using a strategy of 
polymerase chain reaction (PCR) and genomic Southern blot analysis. 
Chimeric, heterozygote, and homozygous m utant mice were generated 
as previously described (12, 17). All studies were performed on F2 
generation litters generated from the breeding of F l heterozygous an ­
imals and on some anim als obtained by breeding F2 homozygous ACE.7 
mice with heterozygous ACE knock-out mice (ACE.1) (12). Age- and 
gender-matched litterm ate  controls were used in all studies. Animal 
procedures were approved by the Institutional Animal Care and Use 
Committee and were supervised by the Emory University Division of 
Animal Research.
G enotyping—Mice were genotvped bv PCR with prim ers 5'-GCCA- 
CATTAGCTCAGTATCCC-3' and 5'-GCATTGCTTAATCCTGGAGTG- 
G-3'. The wild-type ACE allele amplified a DNA fragm ent of 241 bp, 
and the modified ACE.7 allele amplified a DNA fragm ent of 314 bp. A 
second set of primers (5'-GGTTGTTCAGACTACAATCTGACC-3'. 5'-A- 
GCTTCAGGGCTCTGCTTTCCTGC-3'. and 5'-CAGACGAGCTCGGG- 
ATCTGGGTTGTCTGGT-3') was used to amplify a fragm ent of 287 bp 
in the presence of the null ACE.1 allele and a DNA fragm ent of 215 bp 
from the wild-type or the ACE.7-modified allele.
C haracterization o f  the M u ta n t A C E  E n zym e—Mice were exsangui­
nated by cardiac puncture, and blood was collected on ice in heparinized 
tubes. Plasm a was imm ediately frozen and stored a t -8 0  °C. ACE 
activity was then m easured using different substra tes to evaluate the 
separate activity of each ACE domain. Hip-His-Leu and iV-acetyl-Ser- 
Asp-acetyl-Lys-Pro were used as C- and N- domain-specific substra tes 
(6, 18). Angiotensin I is both a C and N domain substra te  (17). Assays 
were performed a t 37 °C with 5 or 10 /ul of mouse plasma during 30 or 
60 min. Substrate concentration was 2.5-fold Km. The rate of hydrolysis 
of all substra tes used was resolved and quantified by reverse HPLC 
(W aters Co. Milford. MA). Results were expressed in nmol/ml/min 
of gen era ted  h ippuric  acid. acetyl-Lys-Pro, and  angiotensin  II, 
respectively.
T issue A C E  E xpression—Tissue ACE activity and W estern blotting 
were performed as previously described (19). For the preparation of 
protein extracts, anim als were euthanized under anesthesia and organs 
were weighted and then frozen in liquid nitrogen. Later, each organ was 
gently homogenized in ACE buffer (HEPES. pH 7.4, 50 mmol/liter; 
NaCl. 150 mmol/liter; ZnCl„, 25 /nmol/liter; and polyvinylidene difluo­
ride. 1 mmol/liter). After centrifugation, the pellets were vigorously 
rehomogenized with ACE buffer containing 0.5% Triton X-100. After a 
second centrifugation, the supernatan t was collected and protein con­
centration was measured with the  BCA protein assay reagent kit 
(Pierce) following the m anufacturer’s instructions. ACE activity was 
measured using the ACE-REA kit from American Laboratory Products 
Company. Ltd. (ALPCO. Windham. NH). ACE activity was defined as 
th a t inhibitable by captopril.
For W estern blotting. 20 fig of total proteins were separated by 
SDS-PAGE on a 10% gel and transferred  to a nitrocellulose membrane. 
The membranes were probed with a 1:250 dilution of a rabbit polyclonal 
anti-mouse ACE antibody and exposed to X-ray film using enhanced 
che mil u mi n esce n ce.
Blood Pressure—Systolic blood pressure was measured using a Vis- 
itech Systems BP2000 (Apex, NC) autom ated tail cuff system as previ­
ously described (12, 20). Briefly, mice were trained  for 5 days prior to 
data collection. Systolic blood pressure was then measured in two sets 
of 10 m easurem ents per day. The systolic blood pressure for an anim al 
was the average blood pressure obtained over 4 days and consisted of 8 
sets of 10 m easurements.
To m easure plasm a levels of angiotensin I and II. mice were exsan­
guinated by cardiac puncture and blood was collected on ice in tubes 
containing potassium-EDTA (1.6 mg/ml), am astatin  (100 /nmol/liter), 
bestatin (100 /nmol/liter), and lisinopril (4 jiig/ml) (14). Plasm a was 
immediately frozen and stored a t -8 0  °C. Angiotensin I and II levels 
were measured by radioimmunoassay as previously described (21).
Blood Pressure a fter In fusion  o f  A ng io tensin  I  a n d  II—Mice were 
anesthetized by an in traperitoneal injection of a ketam ine and xylazine 
m ixture (125 and 12.5 mg/kg. respectively). Anim als were then placed 
on a 37 °C platform throughout the procedure. A polyethylene catheter 
(PE 10; Becton Dickinson) was inserted into the  right carotid artery  for 
direct blood pressure m easurem ent using an MLT844 blood pressure 
transducer (ADInstruments. Colorado Springs. CO). A separate cathe­
te r  was inserted into the left jugu lar vein for drug adm inistration. After 
blood pressure stabilized. 1 jid/g body weight of heparinized saline (50 
units/ml heparin in 0.9% saline) was injected as a control. 1 jiil/g body 
weight of 1 jiiM Ang I or Ang II (Sigma) was then injected, and the 
increase of mean arteria l blood pressure was recorded.


























were m easured by enzymatic assay as previously described (22, 23). 
Briefly, PRC was determined by m easuring th e  in vitro  production of 
angiotensin I by radioimmunoassay after incubation with an excess of 
angiotensinogen from binephrectomized ra t plasma.
P lasm a a n d  U rinary A cSD K P  M easurem ent—For plasm a and uri­
nary AcSDKP determ inations, 10~5 M lisinopril (Merck Sharp and 
Dohme) was added to heparinized tubes to prevent AcSDKP degrada­
tion by ACE. AcSDKP concentration was determined, directly in the 
urine or after methanol extraction from the plasma, by a competitive 
enzyme immunoassay (Spi Bio, Massy, France) as previously described
(24). U rine creatinine w as measured by autom ated enzymatic methods 
(Kodak Biolyzer; Eastm an Kodak).
Anemia, a n d  H em atocrit—To induce anem ia, phenylhydrazine (60 
mg/kg) was adm inistrated intraperitoneally on two consecutive days
(25). Hem atocrit was m easured 1, 3, 5, 8, and 13 days after th e  second 
injection. To m easure hematocrit, mice were bled from th e  tail vein and 
blood collected in heparinized self-sealing capillary tubes (Safe-Tec; 
ClinicalProducts, Inc., Ivyland, PA). These were centrifuged for 4 min a t
12,000 x g  and read in a manual capillary reader.
U rine O sm olality—To determ ine urine concentrating ability, mice 
were w ater deprived for 24 h but given food a d  lib itu m . Before and a t 
the  end of th is 24-h period, a spot urine osmolality was determined 
using a W estcat 5500 vapor pressure osmometer (Wescor, Inc., Logan, 
UT). The mice were allowed to rehydrate for 3 weeks before any other 
experiments.
S ta tis tica l A n a lysis—All data  were expressed as means ± S.E. The 
significance of the  difference between two groups was evaluated by an 
unpaired Student’s t test. The significance of the  difference among 
multiple groups was obtained by analysis of variance analysis. A p  
value of <0.05 was considered statistically  significant.
RESULTS
Generation o f Genetically Modified Mice—Both the ACE N- 
and C-terminal domains contain the protein motif HEMGH 
that is necessary for zinc binding and catalytic activity (Fig. 
1A). In vitro, the conversion of this motif to KEMGK eliminates 
zinc binding and all catalytic activity (6). To generate mice with 
a functional inactivation of the N-terminal domain, we used 
targeted homologous recombination to modify exon 8 as illus­
trated in Fig. IB. A 10.8-kilobase portion of genomic DNA 
served as the template for the construct. In vitro mutagenesis 
was used to convert the zinc-binding histidines (amino acids 
361 and 365) into codons encoding lysines. In addition, a self- 
excising neomycin cassette was positioned within intron 7. This 
cassette consists of a neomycin resistance gene driven by an 
RNA polymerase II promoter and Cre-recombinase driven by 
the testis ACE promoter (15). The cassette is flanked with Lox 
P sites. This neomycin cassette is stable in ES cells and in 
chimeric founder mice. However, it is excised by Cre-recombi­
nase expression in the developing male germ cells of the chi­
meric animals and is therefore absent in F l heterozygous mice. 
This strategy allowed generation of mice with an intact ACE 
gene except for the N-terminal catalytic site mutations and a 
34-bp Lox P sequence in the seventh intron. Because these mice 
were the seventh strain of genetically mutated mice prepared 
in our laboratory, they are referred to as ACE.7; the genotype 
of homozygous mutated animals is termed ACE 7/7, whereas 
the heterozygous and wild-type mice have ACE genotypes 
termed 7/wt and wt/wt.
Targeted homologous recombination of mouse ES cells was 
carried out using standard techniques. Proper genomic target­
ing was verified by PCR, genomic Southern blot analysis using 
a DNA probe 3' to the targeting construct, and selected se­
quence analysis of the ACE gene. To generate homozygous ACE 
7/7 mice, we mated F l  heterozygous mice. O f377 F2 pups, 53% 
were heterozygous (ACE 7/wt), 26% wild-type (ACE wt/wt), and 
22% homozygous m utant (ACE 7/7). We observed no neonatal 
deaths between birth and weaning.
Compound Heterozygote Mice—Previously, our laboratory 
characterized ACE knock-out mice, called ACE.1, that were 
prepared using targeted homologous recombination. The ACE
Fig. 1. Creation of ACE.7 mice. A, the  wild-type ACE protein is an 
ectoenzyme w ith a signal sequence (black bar) a t  the  N term inus of the 
protein. There are two homologous catalytic domains (ha tched  boxes) 
th a t each bear the  amino acid sequence HEMGH. These domains are 
responsible for binding the  two zinc molecules th a t catalyze enzymatic 
activity. Finally, a t the  C term inus of ACE, there  is a hydrophobic 
domain (do tted  box) th a t  is responsible for the  retention of the  protein 
in cell membranes. B, the  wild-type ACE allele is diagramed in th e  "a” 
portion of the  figure. A rrow s  indicate both th e  somatic and testis ACE 
promoters. Black boxes represent exons 1-25 of somatic ACE. A testis- 
specific exon is indicated in the  gray box located between exons 12 and
13. The N-term inal zinc-binding domain is found w ithin exon 8 of 
somatic ACE. The targeting vector is diagramed in the  "b” portion of the 
figure. The left and right arm s of the  targeting  construct were 7.1 - and 
3.7-kb portions of ACE genomic DNA from mouse strain  129. Site- 
directed m utagenesis was used to convert the  zinc-binding domain 
w ithin the  eighth intron from HEMGH to KEMGK (H395K and 
H399K). A self-excising neomycin cassette (A C -N eo ) was inserted into 
the  seventh intron of the  ACE gene. A thym idine kinase cassette, used 
for negative selection, was inserted a t the  5'-end of the  construction. 
The “c” portion of the  figure shows the  ACE gene after successful gene 
targeting. When th is modified allele w as passed through a male animal, 
the  testis ACE promoter, located within the  self-excising neomycin 
cassette, induced Cre-recombinase expression and neomycin cassette 
excision. The final modified ACE allele is shown in "d.” Point m utations 
are present in exon 8, and a residual 34-base pair loxP sequence (gray 
triang le) is present in the  seventh intron.
1 allele is null, and homozygous m utant mice, termed ACE 1/1, 
lack all expression of somatic and testis ACE. The mating of 
ACE.1 heterozygous mice (genotype 1/wt) with ACE 7/7 mice 
generated compound heterozygous mice, termed ACE 1/7, with 
Mendelian fidelity. ACE 1/7 mice have one copy of the ACE null 
allele (the ACE 1 allele) and one copy of the ACE 7 allele 
(N-terminal catalytically inactive).
ACE Expression and Enzymology—To verify the inactivation 



























Fig. 2. ACE su b s tra te  specificity. ACE activity was measured in 
the  plasm a from wild-type (w t /w t ), ACE 7/7, ACE 1/7, and ACE 1/1 
mice using the C-terminal-specific ACE substrate HHL (A), the ACE 
N-terminal-specific substrate  AcSDAcKP (Bj, and angiotensin I (C). 
Plasm a from ACE 7/7 mice showed equivalent C-term inal activity to 
th a t in the  plasma of wild-type mice. In contrast, plasm a from ACE 7/7 
mice had very little  activity against the  N-terminal-specific substrate. 
Plasm a from ACE 1/7 mice showed 65 and 56% the activity of ACE 7/7 
plasm a against the  C-terminal substrate  HHL and angiotensin I, re­
spectively. Plasm a from 1/1 mice showed catalytic activity below the 
detection lim it (< D L ) against any ACE substrate. In each panel, n = 11 
(wt/wt), 14 (7/7), 10 (1/7), and 5'(1/1).
catalytic activity of plasma using synthetic ACE substrates 
specific for either the C- or N-terminal catalytic domains (Fig. 
2A). To measure C-terminal catalytic activity, the substrate 
HHL was used. As anticipated, there was no significant differ­
ence in enzymatic activity between plasma from wild-type (wt/ 
wt) and ACE 7/7 mice with this substrate. In contrast, ACE 1/7 
mice had a 35% reduction of catalytic activity, reflecting re­
duced ACE expression because of the ACE 1 allele. Plasma 
from ACE 1/1 mice showed no activity against HHL or any ACE 
substrate.
To investigate N-terminal ACE catalytic activity, hydrolysis 
of the N-terminal-specific peptide AcSDAcKP was measured
(Fig. 2B). This peptide was efficiently cleaved by wild-type 
plasma, but very little enzymatic activity was exhibited by the 
plasma from ACE 7/7 mice (3.3 ± 1.1% ofwild-type). We believe 
this residual activity is low-level cleavage of the substrate by 
the C-terminal domain and not nonspecific hydrolysis, because 
plasma from ACE 1/1 mice showed no such activity.
We also investigated the ability of plasma ACE to convert 
angiotensin I to angiotensin II (Fig. 2 0 . ACE activity in 7/7 
plasma was 68% that of wild-type mice. A reduction of about 
this magnitude was expected, given the known KCBt values for 
angiotensin I hydrolysis by each of the two ACE catalytic 
domains (11 s_1 for the N terminus, 34 s_1 for the C terminus ). 
Also as expected, the ACE 1/7 plasma showed activity that was 
38 and 56% that of wild-type and ACE 7/7 plasma, respectively. 
Thus, the enzymatic characterization of ACE 7/7 and ACE 1/7 
mice is consistent with our molecular genotype and establishes 
that these mice produce an ACE protein that lacks N-terminal 
catalytic activity. ACE 1/7 mice produce less of this enzyme 
because of the presence of the ACE 1 null allele.
Although ACE is found in plasma, the majority of the protein 
in an animal is bound to tissues such as the lung or kidney. To 
quantitate the tissue expression of ACE, we prepared detergent 
homogenates of lung, kidney, testis, brain, heart, and liver 
from wild-type, ACE 7/7, and ACE 1/7 mice (Fig. 3A). First, we 
measured ACE activity using [3H]hippuryl-glycylglycine as a 
substrate. This showed a consistent pattern exemplified by 
lung ACE expression. Compared with wild-type, ACE 7/7 mice 
had a modest reduction of activity (20%). This is probably due 
to a lack of N-terminal activity against this substrate. An 
equivalent reduction was observed in all tissues examined. In 
contrast, lung ACE activity in ACE 1/7 mice was 46 and 58% of 
wild-type and ACE 7/7. As with plasma, these figures reflect 
reduced ACE protein.
To directly evaluate levels of protein expression, Western 
blot analysis was performed on the tissue homogenates using a 
polyclonal rabbit anti-mouse ACE antibody (Fig. 3B). Wild-type 
ACE is a protein of — 170 kDa, whereas testis ACE is 95 kDa. 
As with ACE activity, all organs showed a similar pattern in 
which there was no difference in ACE expression between 
wild-type and ACE 7/7 mice. In contrast, ACE 1/7 mice showed 
a reduction of somatic ACE that reflected the presence of the 
ACE.1 allele, which is null for ACE expression. All three groups 
of mice showed an equivalent amount of testis ACE. This is 
expected, because our strategy does not affect either the ex­
pression or activity of this isozyme.
Blood Pressure—To study the physiology of the mice, systolic 
blood pressure was measured in wild-type (wt/wt), heterozy­
gous (7/wt), ACE 7/7, and ACE 1/7 mice (Fig. 4). Blood pressure 
was obtained in conscious, trained mice by tail cuff measure­
ment. Fig. 4 shows the individual blood pressure determina­
tions as well as the group mean for each genotype. Both ACE 
7/7 and ACE 1/7 mice have systolic blood pressures indistin­
guishable from those of wild-type or heterozygous mice ( 7/wt). 
Specifically, whereas wild-type mice had an average blood pres­
sure of 105.0 ± 2.2 mm Hg, ACE 7/7 and 1/7 mice had average 
systolic blood pressures of 110.1 ± 2.2 and 107.8 ± 1.9 111111 Hg.
Angiotensin and AcSDKP Peptide Levels—To understand 
blood pressure control in ACE 7/7 and ACE 1/7 mice, we meas­
ured the plasma concentrations of angiotensin I and II. As seen 
in Fig. 5, these peptides are found in levels identical to those 
measured in wild-type mice. Thus, the inactivation of the N- 
terminal catalytic domain had 110 effect 011 the ability of ACE 
7/7 mice to produce plasma angiotensin II. Indeed, the normal 
plasma levels of angiotensin I suggest that there is little com­
pensation of the RAS necessary for maintaining normal blood 

























Fig. 3. Tissue ACE expression. A , ACE activity was measured in tissue homogenates using the  substrate  pHlhippuryl-glycylglycine. In lung 
tissue, ACE 7/7 mice (gray boxes) had a modest reduction of ACE activity compared with wild-type anim als (black boxes). A sim ilar small reduction 
of ACE activity (compared w ith wild-type) was seen in all the  organs from ACE 7/7 mice. ACE 1/7 mice (hatched boxes) showed a much more marked 
reduction of ACE activity. The num ber of mice measured in each group was 6. B, ACE protein was quantitated  using W estern blot analysis of tissue 
homogenates. ACE was detected using a polyclonal rabbit anti-ACE antibody. Somatic ACE (sACE) is a protein of -170 kDa, whereas testis ACE 
(tACE) is 95 kDa. Tissue ACE levels in ACE 7/7 mice were no different from those of wild-type (wt) mice. In contrast, ACE 1/7 mice showed a 
significantly sm aller am ount of somatic ACE protein compared with e ither wild-type or ACE 7/7 mice. Testis ACE expression was not different 
between the  three  genotypes. The left and rig h t p a nels  were exposed to x-ray film for 5 s and 1 min, respectively.
ACE 7/7, ACE 1/7, and ACE 1/1 mice. This confirms the above 
conclusion because the concentration of renin in the plasma of 
ACE 7/7 mice is not different from that of wild-type. Not sur­
prising, the ACE 1/7 mice have an elevation of plasma renin in 
response to the reduced expression of ACE (2.3-fold wild-type, 
p  <0.02). However, this is far smaller in magnitude than the 
increase of renin levels observed in ACE 1/1 mice.
To evaluate ACE function in the ACE 7/7 and ACE 1/7 mice, 
we measured the change in blood pressure after the acute 
intravenous infusion of angiotensin I and compared this to the 
change in blood pressure after intravenous infusion of angio­
tensin II (Fig. 6). For this experiment, mice were anesthetized 
and prepared with an arterial catheter to continually monitor 
blood pressure. A venous catheter was used for peptide infu­
sion. These studies showed no difference in response in the 
magnitude, time response, or shape of the pressure curves 
between wild-type and either ACE 7/7 or ACE 1/7 mice. As a 
control, we used a strain of ACE knock-out mice called ACE 4/4 
(26). These mice are similar to ACE null mice (ACE 1/1) except 
that they retain normal expression of testis ACE. As expected 
for animals deficient in somatic ACE, their response to angio­
tensin I was markedly diminished. These experiments show 
that, functionally, ACE 7/7 and even ACE 1/7 mice are able to
Fig. 4. Blood pressure. Systolic blood pressure was measured in 
conscious wild-type (w t/w t), heterozygous (7/w t), ACE 7/7, and ACE 1/7 
mice. Blood pressure was measured using an autom ated tail cuff as 
previously described (12, 20). Individual blood pressure determ inations 
are indicated (dashes) as well as group m eans ( • )  ± S.E. There was no 
significant difference in blood pressure between any of the  four groups. 




























Fig. 5. Plasma angiotensin and renin concentration. A  and B ,
plasm a angiotensin I and II peptide levels were determ ined by radio­
im m unoassay for wild-type (w th v t), ACE 7/7, and 1/7 mice, n  = 8 
(wt/wt), 12 (7/7), 11 (1/7). C', plasma renin concentration was measured in 
the presence of an excess of rodent angiotensinogen. Wild-type (wt/wt) and 
ACE 7/7 mice have the same plasma renin concentration. In contrast, 
plasma renin was elevated in ACE 1/7 mice (hatched box, p  <0.02) and 
markedly elevated in ACE knock-out mice (1/1). n  = 11 (wt/wt), 14 (7/7), 
10 (1/7), 4 (1/1).
Fig. 6. Infusion of angiotensin I and II. Mice were anesthetized 
and prepared with both venous and arteria l catheters. After stabiliza­
tion of blood pressure, the  increase in m ean arteria l blood pressure in 
response to angiotensin I and II infusions was m easured in wild-type 
(w thvt), ACE 7/7, ACE 1/7, and ACE knock-out (414) mice. The da ta  are 
plotted as the pressure increase in response to angiotensin I divided by 
the  increase in response to angiotensin II. There is no significant 
difference in the  response of wild-type, ACE 7/7, and ACE 1/7 mice to 
the  peptide infusion. In contrast, ACE 4/4 mice have a  m uch reduced 
response to angiotensin I infusion, n  = 5 (wt/wt), 6 (7/7), 4 (1/7), 3 (4/4).
Fig. 7. Urine concentration of AcSDKP. The concentration of the 
tetrapeptide AcSDKP was determined by enzyme-linked immunosor­
bent assay in the  urine of wild-type (w thvt), ACE 7/7, and ACE 1/7 mice. 
AcSDKP concentrations were corrected for the  creatinine concentra­
tions. The concentrations of AcSDKP were increased in those mice 
lacking the  N term inus catalytic site of ACE. n  = 8 (wt/wt), 9 (7/7), 10 
(1/7).
efficiently process angiotensin I. The lack of any difference 
between these mice and wild-type suggests that the ACE C- 
terminal catalytic site alone is sufficient for the processing of 
angiotensin I.
A specific substrate of the ACE N-terminal catalytic domain 
is the tetrapeptide AcSDKP (7). Clinical evaluation of patients 
treated with ACE inhibitors showed a marked elevation of 
plasma and urinary AcSDKP concentrations (27-29). Further, 
ACE null mice have elevated AcSDKP plasma concentrations, 
which raised the question as to whether the anemia in these 
animals may, in part, be due to this peptide. To study this 
question, we measured concentrations of AcSDKP in ACE.7 
mice (Fig. 7). In plasma, the levels of this peptide were elevated 
in both ACE 7/7 and ACE 1/1 mice as compared with wild-type 
(data not shown). The AcSDKP levels in urine are also elevated 
in the groups lacking N-terminal ACE activity (ACE 7/7 and 
ACE 1/7). For example, whereas wild-type mice have urinary 
AcSDKP levels of about 21 pmol/mmol creatinine, ACE 7/7 
mice have levels of 155 pmol/mmol creatinine. As discussed 
below, these differences in urinary AcSDKP are not because of 
differences in urinary concentrating ability. A possible expla­
nation is that, normally, renal ACE may degrade urinary AcS­
DKP and, in the absence of ACE with a functional N-terminal 
catalytic activity, there is a marked elevation of peptide 
concentration.
AcSDKP has been suggested as an erythrocyte lineage bone 
marrow-suppressive peptide (30). Because levels of this peptide 
are elevated in ACE 7/7 and ACE 1/7 mice and reach a similar 
level to that noted in ACE 1/1 mice, we measured the hemato­
crit in these mice. As shown in Fig. 8A, there was no significant 
difference between the hematocrit of wild-type, heterozygous, 
ACE 7/7, and ACE 1/7 mice. We also studied the response to 
anemia. Red blood cell lysis was induced by injecting the mice 
with phenylhydrazine (Fig. SB). In the recovery from the ane­
mia, there was no significant difference between wild-type, 
ACE 7/7, and ACE 1/7 mice. These data suggest that, in mice, 
the elevations of AcSDKP seen in the absence of N-terminal 
ACE activity are not associated with major disturbances of 
erythropoiesis. Because AcSDKP is an N-terminal-specific sub­
strate of ACE, the anemia observed in ACE null mice is prob­
ably due to factors other than AcSDKP.

























Fig. 8. Hematocrit. A , hem atocrit was m easured for wild-type {lot/ 
ivt), heterozygous {7/wt), ACE 7/7, and ACE 1/7 mice (n = 13-24 for each 
group). Individual m easurem ents are indicated by a dash . The group 
m ean is represented by a ( • )  ± S.E. No significant differences were 
noted. B , phenvlhvdrazine was adm inistered intraperitoneallv on davs 
1 and 2 {.arrows) to wild-type (■). ACE 7/7 (A). and ACE 1/7"(O) mice. 
Hem atocrit was m easured as indicated. Control, wild-type mice (♦ ). 
were injected w ith saline alone. No significant differences were ob­
served for hem atocrit recovery of wild-type. ACE 7/7, and 1/7 mice, n  = 
5 for wt/wt and ACE 7/7; n  = 4 for ACE 1/7 and control mice.
there is expansion of the renal calyx, underdevelopment of the 
medulla and papilla, thickening of renal arterioles, and the 
inability to concentrate urine (12). ACE 7/7 and ACE 1/7 mice 
were evaluated for renal concentrating ability by water restric­
tion for 24 h (Fig. 9). These animals behaved identically to 
wild-type mice. With water present ad libitum, all groups of 
mice produced urine with an average osmolality of about 2000 
mosM/liter. In response to water deprivation, all groups ele­
vated urinary osmolality to greater than 3,500 mosM/liter. At 
sacrifice, careful evaluation showed normal gross renal devel­
opment in the ACE 7/7 and ACE 1/7 mice. Histologic examina­
tion confirmed no significant differences between ACE 7/7, 
ACE 1/7, and wild-type mice.
D ISC U SSIO N
For many years, ACE was thought to have a single catalytic 
domain (31), but the cloning of the mammalian gene showed a 
more complex structure (5, 32). It is now known that somatic 
ACE is composed of two homologous protein domains, each of 
which binds zinc and each of which is catalytic (8 ). Although 
the two domains of ACE are —68% identical in amino acid 
sequence, higher conservation (89%) is present in the center of 
each domain where amino acids active in catalysis have been 
identified by comparison with the active sites of other metal- 
lopeptidases. ACE is encoded by a single genetic locus located 
on human chromosome 17 (mouse chromosome 11) where each 
of the two catalytic domains of the enzyme is encoded by a 
cluster of eight exons. In each domain, the corresponding exons 
are similar in size and in the codon phase at the exon/intron 
boundaries. The similarities of the exon/intron organization of 
the two clusters strongly suggest that the mammalian ACE 
gene is the result of an ancestral gene duplication. Interest­
ingly, the ACE locus contains two ACE promoters that give rise 
to two distinct ACE isozymes: somatic and testis ACE. The
Fig. 9. Renal concentrating ability. Spot urine was collected and 
osmolality was m easured for wild-type {iothot), heterozygous {iot/7), 
ACE 7/7, and ACE 1/7 mice under conditions of free w ater availability
•
values are shown by a d a sh . We found no difference in  concentrating 
ability between the different groups of mice, n  >  13 for each group.
testis ACE promoter is located in the twelfth intron of the 
somatic ACE gene and testis ACE corresponding to the C- 
terminal half of the somatic ACE protein.
The presence of testis ACE with a single catalytic domain 
and the identification of ACE homologs in Drosophila, also with 
a single catalytic domain (33), inevitably raises the question as 
to why mammalian somatic ACE has retained a gene duplica­
tion during evolution. Specifically, scientists have wondered 
whether the gene duplication resulted in specific properties of 
ACE that are critical for its diverse physiologic roles. Although 
the two domains of somatic ACE are highly homologous, their 
biochemical properties are slightly different in terms of chlo­
ride dependence, inhibitor affinity, and substrate kinetics (7, 
9). For example, both angiotensin I and bradykinin are cleaved 
with near equal efficiency by the two ACE catalytic domains. In 
contrast, some substrates, such as AcSDKP, are much more 
efficiently hydrolyzed by one catalytic domain (in the case of 
AcSDKP, it is the N-terminal domain). To investigate the phys­
iologic importance of the two ACE catalytic domains in vivo, we 
generated a new mouse model in which the N-terminal domain 
of ACE was inactivated without any alteration of protein ex­
pression. Because the ACE modification involved point m uta­
tions impairing the zinc-binding properties of the N-terminal 
catalytic site, the tissue pattern of expression and the level of 
protein expression are no different from wild-type mice. This 
approach is different from that used by Kessler et al. who 
created a transgenic mouse model in which rabbit testis ACE 
was expressed under the control of a tissue-specific promoter 
(Tie-1 or -y-glutamyltransferase) in a background mouse strain 
that was null for the endogenous ACE gene (an ACE knock-out 
mouse (40)). Evaluation of ACE 7/7 mice showed that ACE 
enzymatic properties were consistent with our genetic design. 
The conversion of angiotensin I to angiotensin II in plasma was 
68% that of wild-type mice. In contrast, ACE 7/7 mice hydro­
lyzed AcSDAcKP with only 3% of the efficiency of control mice 
and had an elevation of both plasma and urine concentrations 
of AcSDKP. AcSDKP was initially purified from bone marrow 
and described as a regulator of hematopoiesis (30). It inhibits 
the proliferation of hematopoietic stem cells in vitro and when 
injected in mice (34-38). Because of this, it was hypothesized 
that the anemia observed in ACE knock-out mice might be the 
consequence of the accumulation of this peptide. ACE 7/7 mice 



























surprisingly, have no reduction of hematocrit. Further, ACE 
7/7 and ACE 1/7 mice reconstitute a normal hematocrit after 
chemically induced anemia with the same time course as wild- 
type mice. These data suggest that AcSDKP accumulation in 
ACE 7/7 mice has no significant effect on erythropoiesis. This 
conclusion is consistent with a study of ACE-deficient mice 
suggesting that the anemia in these animals may be because of 
reduced levels of angiotensin II (14). In fact, infusion of angio­
tensin II in these mice restored a normal hematocrit.
We also studied ACE 1/7 mice in which one of the two ACE 
alleles is null, resulting in only a single functional ACE allele 
that itself lacks N-terminal catalytic activity. In this model, 
tissues such as the lung have approximately half the ACE 
activity seen in ACE 7/7 mice and —42% the activity of wild- 
type mice. Not surprising, plasma renin activity in ACE 1/7 
mice was significantly greater than either wild-type or ACE 7/7 
mice. However, comparison of the renin levels in ACE 1/7 mice 
versus those present in ACE 1/1 knock-out animals immedi­
ately demonstrated that the compensatory ability of the RAS 
was far from maximally engaged in the ACE 1/7 model. Per­
haps because of this, the phenotype of ACE 1/7 mice was 
identical to wild-type in terms of blood pressure, renal struc­
ture, renal concentrating ability, and hematocrit.
In humans, the deletion/insertion (D/I) polymorphism of the 
ACE gene is associated with changes in plasma levels of ACE 
(39). Humans with the I/I phenotype have —63% the plasma 
ACE of D/D individuals. Thus, for the conversion of angiotensin 
I to angiotensin II, the human I/I phenotype may be compared 
with the reduction of plasma ACE found in ACE 1/7 mice. Many 
human studies have examined the pathophysiologic effects of 
the ACE polymorphisms, and the literature is both complicated 
and contradictory. In our experience, we saw no increased 
mortality of ACE 1/7 mice as compared with wild-type. How­
ever, in these animals, we have not formally evaluated the 
disease models, such as heart disease and diabetes, that have 
been the subject of human studies.
In summary, we have created model strains of mice in which 
point mutations were introduced into the ACE N-terminal cat­
alytic domain, rendering this domain catalytically inactive. In 
both the homozygous m utant mouse (ACE 7/7) and a compound 
heterozygous mouse (ACE 1/7), blood pressure control was no 
different from wild-type mice. Indeed, the normal phenotype of 
these mice suggests that the two ACE catalytic domains are 
functionally redundant. Although the N-terminal catalytic do­
main hydrolyzes unique substrates such as AcSDKP, we see no 
unique physiologic effects of this catalytic site under the pres­
ent experimental conditions.
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